ReviewEndocrinology, diabetes & metabolism2026
Global Landscape and Thematic Evolution of Selective GLP-1 Receptor Agonists and GLP-1-Based Multi-Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis.
Review in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimTo characterize the global development, collaboration structure, publication landscape, citation influence and thematic evolution of research on selective GLP-1 receptor agonists and GLP-1-based multi-receptor agonists in T2DM.
methodsA bibliometric analysis was conducted on 3736 original articles published between 2004 and 2025 and retrieved from the Web of Science Core Collection. Publication trends, research contributions, collaboration networks, citation impact and thematic evolution were evaluated using complementary bibliometric indicators and network analysis.
resultsAnnual publication output increased substantially. Selective-only studies remained the cumulative core of the evidence base, while mixed/comparative and multi-receptor-only studies expanded rapidly in recent years. The United States led in research output and international connectivity, and Novo Nordisk and Eli Lilly were the most prominent institutional contributors based on author affiliation analysis. Diabetes, Obesity and Metabolism was the leading source journal. Research output was highly concentrated across countries but more widely distributed across institutions and authors. Thematic emphasis shifted from incretin biology and glycemic efficacy toward cardiovascular and kidney outcomes, obesity, integrated treatment strategies and real-world evidence. Major trials, particularly LEADER and REWIND, and ADA/EASD consensus statements exerted strong citation influence. Sensitivity analysis supported the overall robustness of the principal findings.
conclusionsResearch on GLP-1-based agonists in T2DM has expanded rapidly and shifted toward an integrated cardiovascular-kidney-metabolic framework. Studies of selective GLP-1RAs remain central to the literature, while studies of newer GLP-1-based multi-receptor agonists are contributing to its diversification. Evidence remains comparatively less developed for longer-term outcomes of emerging agents, treatment sustainability in routine care, patient experience and diverse populations and settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.